Additional intervention trials are necessary to investigate whether treating low grade albuminuria with angiotensin receptor blocker (ARB) or/and angiotensin converting enzyme (ACE) inhibitor therapy can reduce the risk for cardiovascular disease and mortality. The gene discussed is ACE; the disease is cardiovascular disorder.